Enlivex Therapeutics Ltd. (ENLV) Company Information

Complete company information for ENLV including business overview, key executives, headquarters location, corporate structure, and company details. Learn about ENLVleadership team and business operations.

Company Profile

Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.

Sector: Healthcare

Industry: Biotechnology

Website: https://www.enlivex.com

Headquarters: 14 Einstein Street, Ness Ziona, 7403618, Israel

Phone: 972 2 620 8072

Full Time Employees: N/A

Key Executives:

Executive Chairman: Mr. Shai Novik M.B.A.Total Pay: $528,000

Chief Executive Officer: Dr. Oren Hershkovitz Ph.D.Total Pay: $273,600

Founder & Scientific Advisor: Prof. Dror Mevorach M.D.Total Pay: $180,000

Chief Financial Officer: Ms. Shachar Shlosberger CPATotal Pay: $126,000

Senior Director of Operations: Dr. Veronique Amor-Baroukh